Search for 'an,phr: 389'

Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.

By Valeri, Antonio | Martínez López, Joaquín. Blood, 2016 . 128(18):2241-52. , Formato Vancouver: Gutiérrez González A, Martínez Moreno M, Samaniego R, Arellano Sánchez N, Salinas Muñoz L, Relloso M et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 2016 Nov 3;128(18):2241-52.

Place Hold on Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.

By Martínez López, Joaquín. British journal of haematology, 2016 . 175(3):448-56. , Formato Vancouver: Mateos MV, Granell M, Oriol A, Martínez López J, Blade J, Hernandez MT et al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016 Nov;175(3):448-56.

Place Hold on Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.

Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients.

By Martínez López, Joaquín | Lahuerta Palacios, Juan José . American journal of hematology, 2016 . 91(7):700-4. , Formato Vancouver: Ríos Tamayo R, Sáinz J, Martínez López J, Puerta JM, Chang DY, Rodríguez T et al. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. Am J Hematol. 2016 Jul;91(7):700-4.

Place Hold on Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

By Martínez López, Joaquín. Leukemia, 2016 . 30(9):1844-52. , Formato Vancouver: Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia. 2016 Sep;30(9):1844-52.

Place Hold on Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.

By Martínez López, Joaquín. Annals of hematology, 2016 . 95(5):719-32. , Formato Vancouver: Besses C, Hernández Boluda JC, Pérez Encinas M, Raya JM, Hernández Rivas JM, Jiménez Velasco A et al; GEMFIN. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. Ann Hematol. 2016 Apr;95(5):719-32.

Place Hold on Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

By Martínez López, Joaquín. Haematologica, 2016 . 101(7):872-8. , Formato Vancouver: Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016 Jul;101(7):872-8.

Place Hold on Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.

By Martínez López, Joaquín. Oncotarget, 2016 . 7(37):59029-48. , Formato Vancouver: Ríos Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez López J et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget. 2016 Sep 13;7(37):59029-48.

Place Hold on A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.

Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

By Martínez López, Joaquín. Endocrine-related cancer, 2015 . 22(4):545-59. , Formato Vancouver: Ríos R, Lupiañez CB, Campa D, Martino A, Martínez López J, Martínez Bueno M et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer. 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029. Epub 2015 Jun 22..

Place Hold on Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets.

By Martínez López, Joaquín | Rodríguez Izquierdo, Antonia . Leukemia & lymphoma, 2016 . 57(1):134-42. , Formato Vancouver: Cordoba R, Sánchez Beato M, Herreros B, Domenech E, Garcia Marco J, García JF et al. Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. Leuk Lymphoma. 2016;57(1):134-42.

Place Hold on Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets.

Treatment for patients with newly diagnosed multiple myeloma in 2015.

By Martínez López, Joaquín | Lahuerta Palacios, Juan José . Blood reviews, 2015 . 29(6):387-403. , Formato Vancouver: Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez López J, Bladé J et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 2015 Nov;29(6):387-403.

Place Hold on Treatment for patients with newly diagnosed multiple myeloma in 2015.

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

By Martínez López, Joaquín. Cancer medicine, 2015 . 4(7):995-1002. , Formato Vancouver: Casado LF, García Gutiérrez JV, Massagué I, Giraldo P, Pérez Encinas M, de Paz R et al. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. Cancer Med. 2015 Jul;4(7):995-1002.

Place Hold on Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.

By Martínez López, Joaquín. Cancer, 2015 . 121(21):3809-17. , Formato Vancouver: Ribera J, Morgades M, Zamora L, Montesinos P, Gómez Seguí I, Pratcorona M et al; Spanish PETHEMA Group and the Spanish Society of Hematology. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015 Nov 1;121(21):3809-17.

Place Hold on Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

By Martínez López, Joaquín. Leukemia research reports, 2015 . 4(2):64-9. , Formato Vancouver: López A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep. 2015 Sep 24;4(2):64-9.

Place Hold on Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor.

By Martínez López, Joaquín | Jiménez Ubieto, Ana Isabel | Urbanowicz, María | Cañamares Orbis, I. | Cortijo Cascajares, Susana | Ayala Díaz, Rosa María. Annals of hematology, 2015 . 94(7):1237-9. , Formato Vancouver: Martínez López J, Jiménez A, Sánchez Calero J, Monteagudo D, Urbanowicz M, Cañamares Orbis I et al. Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. Ann Hematol. 2015 Jul;94(7):1237-9.

Place Hold on Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

By Martínez López, Joaquín. Haematologica, 2015 . 100(10):1334-9. , Formato Vancouver: San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015 Oct;100(10):1334-9.

Place Hold on Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

By Rapado Martínez, Inmaculada | Martínez López, Joaquín. Cancer cell, 2015 . 28(4):486-499. , Formato Vancouver: Gallardo M, Lee HJ, Zhang X, Bueso Ramos C, Pageon LR, McArthur M et al. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell. 2015 Oct 12;28(4):486-499.

Place Hold on hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

By Martínez López, Joaquín. Nature communications, 2015 . 6:7539. , Formato Vancouver: Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun. 2015 Jul 22;6:7539.

Place Hold on Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Deep Response in Multiple Myeloma: A Critical Review.

By Martínez López, Joaquín. BioMed research international, 2015 . 2015:832049. , Formato Vancouver: Fulciniti M, Munshi NC, Martínez López J. Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int. 2015;2015:832049.

Place Hold on Deep Response in Multiple Myeloma: A Critical Review.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

By Martínez López, Joaquín. Haematologica, 2015 . 100(10):1327-33. , Formato Vancouver Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33.

Place Hold on Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

By Martínez López, Joaquín | López Anglada, Lucía | Cedena Romero, María Teresa | Sáez Gómez, María Auxiliadora | Rapado Martínez, Inmaculada | Cueto Felgueroso, Cecilia | Lahuerta Palacios, Juan José . Blood, 2015 . 126(7):858-62. , Formato Vancouver: Martínez López J, Paiva B, López Anglada L, Mateos MV, Cedena T, Vidríales MB et al; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015 Aug 13;126(7):858-62.

Place Hold on Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

CALR mutations screening should not be studied in splanchnic vein thrombosis.

By Castro Quismondo, Nerea | Rapado Martínez, Inmaculada | Ayala Díaz, Rosa María | Martínez López, Joaquín. British journal of haematology, 2015 . 170(4):588-9. , Formato Vancouver: Castro N, Rapado I, Ayala R, Martínez López J. CALR mutations screening should not be studied in splanchnic vein thrombosis. Br J Haematol. 2015 Aug;170(4):588-9.

Place Hold on CALR mutations screening should not be studied in splanchnic vein thrombosis.

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

By Martínez López, Joaquín. Haematologica, 2015 . 1096-102. , Formato Vancouver: Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J et al. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial. Haematologica. 2015 Aug;100(8):1096-102.

Place Hold on Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III.

By Carreño Gómez-Tarragona, Gonzalo | Trapiello Valbuena, Francisco | Aranda Salom, Judit | Martínez López, Joaquín | Lumbreras Bermejo, Carlos | Oliveira Ramírez, Encarnación | Díaz Pedroche, María del Carmen. Annals of hematology, 2015 . 94(8):1411-2. , Formato Vancouver: Carreño Tarragona G, Trapiello Valbuena F, Aranda Salom J, Martínez López J, Lumbreras C, Oliveira Ramírez E et al. Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III. Ann Hematol. 2015 Aug;94(8):1411-2.

Place Hold on Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III.

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

By Martínez López, Joaquín. Haematologica, 2014 . 99(4):e55-7. , Formato Vancouver: Hernández Boluda JC, Pereira A, Gómez M, Boqué C, Ferrer Marín F, Raya JM et al; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica. 2014 Apr;99(4):e55-7.

Place Hold on The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

By Martínez López, Joaquín | Lahuerta Palacios, Juan José | Barrio García, Santiago | Ayala Díaz, Rosa María | Montalbán Pallarés, María Ángeles | Sopeña Corvinos, María | Cedena Romero, María Teresa | Rapado Martínez, Inmaculada. Blood, 2014 . 123(20):3073-9. , Formato Vancouver: Martínez López J, Lahuerta JJ, Pepín F, González M, Barrio S, Ayala R. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014 May 15;123(20):3073-9.

Place Hold on Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.

By Martínez López, Joaquín. Clinical lymphoma, myeloma & leukemia, 2014 . 14(4):305-18. , Formato Vancouver: Bennett TA, Montesinos P, Moscardo F, Martinez Cuadron D, Martinez J, Sierra J et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):305-18.

Place Hold on Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.

Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era.

By Martínez López, Joaquín. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014 . 23(4):670-4. , Formato Vancouver: Martino A, Campa D, Jurczyszyn A, Martínez-López J, Moreno MJ, Varkonyi J et al. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):670-4.

Place Hold on Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era.

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?.

By Martínez López, Joaquín | Montalbán Pallarés, María Ángeles | Lahuerta Palacios, Juan José . Blood, 2014 . 124(12):1887-93. , Formato Vancouver: Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood. 2014 Sep 18;124(12):1887-93.

Place Hold on GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?.

Protocolo Docente de Hematología y Hemoterapia (2010)

By Martínez López, Joaquín | Cedena Romero, María Teresa. Madrid: Hospital Universitario 12 de Octubre, 2010 . 32 p. ; 30 cm..

Place Hold on Protocolo Docente de Hematología y Hemoterapia (2010)

Proyecto Técnico de Gestión Jefatura del Servicio de Hematología Hospital Universitario "12 de Octubre". Convocatoria BOCM, 15 de Diciembre de 2015

By Martínez López, Joaquín. Madrid : Hospital Universitario 12 de Octubre, 2016 . 158 p. ; 30 cm..

Place Hold on Proyecto Técnico de Gestión Jefatura del Servicio de Hematología Hospital Universitario "12 de Octubre". Convocatoria BOCM, 15 de Diciembre de 2015

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?.

By Martínez López, Joaquín. American journal of hematology, 2014 . 89(11):E206-11. , Formato Vancouver: García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR et al. Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor? Am J Hematol. 2014 Nov;89(11):E206-11.

Place Hold on Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?.

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma.

By Martínez López, Joaquín | Lahuerta Palacios, Juan José . Leukemia, 2014 . 28(2):391-7. , Formato Vancouver: Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014 Feb;28(2):391-7.

Place Hold on Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma.

Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

By Martínez López, Joaquín. Haematologica, 2014 . 99(7):e98-101. , Formato Vancouver: Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond C et al. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica. 2014 Jul;99(7):e98-101.

Place Hold on Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

By Ayala Díaz, Rosa María | Fernández Redondo, Elena | Lahuerta Palacios, Juan José | Martínez López, Joaquín | Martínez Sánchez, María Pilar | Montalbán Pallarés, María Ángeles. British Journal of Haematology, 2013 . 163(5):581-9. , Formato Vancouver: Martínez López J, Fernández Redondo E, García Sanz R, Montalbán MA, Martínez Sánchez P, Pavia B, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013;163(5):581-9.

Place Hold on Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Montalbán Pallarés, María Ángeles. Leukemia, 2013 . 27(10):2056-61. , Formato Vancouver: Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM et al. Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013 Oct;27(10):2056-61.

Place Hold on A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín. Haematologica, 2013 . 98(1):79-86. , Formato Vancouver: Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernández-Giménez C, García-Sanz R, Mateos MV et al. Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013 Jan;98(1):79-86.

Place Hold on Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín. Clinical Cancer Research, 2013 . 19(17):4770-9. , Formato Vancouver: Puchades-Carrasco L, Lecumberri R, Martínez-López J, Lahuerta JJ, Mateos MV, Prósper F et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013 Sep 1;19(17):4770-9.

Place Hold on Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission.

Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.

By Martínez López, Joaquín. Leukemia, 2013 . 27(4):925-31. , Formato Vancouver: Río-Machín A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvárez S. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013 Apr;27(4):925-31.

Place Hold on Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

By Martínez López, Joaquín. The Lancet. Oncology, 2013 . 14(11):1055-66. , Formato Vancouver: Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-1066.

Place Hold on Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Fernández Redondo, Elena. British Journal of Haematology, 2013 . 163(2):223-34. , Formato Vancouver: Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B et al. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. Br J Haematol. 2013 Oct;163(2):223-34.

Place Hold on Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera.

By Arenas Cortés, Alicia | Ayala Díaz, Rosa María | Barrio García, Santiago | Gallardo, Miguel | Garcia Martin, Rosa Maria | Gilsanz Rodríguez, Florinda | Jiménez Ubieto, Ana Isabel | Martínez López, Joaquín | Toldos González, Oscar. Molecular cancer, 2013 . 12:142. , Formato Vancouver: Gallardo M, Barrio S, Fernández M, Paradela A, Arenas A, Toldos O et al. Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Mol Cancer. 2013 Nov 19;12:142.

Place Hold on Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera.

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms.

By Arenas Cortés, Alicia | Ayala Díaz, Rosa María | Barrio García, Santiago | Gilsanz Rodríguez, Florinda | Jiménez Ubieto, Ana Isabel | Martínez López, Joaquín | Rapado Martínez, Inmaculada | Rueda Fernández, Daniel. Blood, 2013 . 161(5):667-76. , Formato Vancouver: Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D et al. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. Br J Haematol. 2013 Jun;161(5):667-76.

Place Hold on Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms.

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.

By Sánchez Pérez, Ricardo | Ayala Díaz, Rosa María | Alonso Fernández, Rafael Alberto | Martínez Sánchez, María Pilar | Sánchez Pina, José María | Martínez López, Joaquín. Annals of Hematology, 2017 . 96(7):1069-1075. , Formato Vancouver: Sánchez R, Ayala R, Alonso RA, Martínez MP, Ribera J, García O et al. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Ann Hematol. 2017 Jul;96(7):1069-1075.

Place Hold on Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Montalbán Pallarés, María Ángeles. The American Journal of Pathology, 2012 . 181(5):1870-8. , Formato Vancouver: Paiva B, Vídriales MB, Montalbán MÁ, Pérez JJ, Gutiérrez NC, Rosiñol L, et al. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. Am J Pathol. 2012 Nov;181(5):1870-8.

Place Hold on Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín | Martín Ramos, María Luisa. Blood, 2012 . 120(8):1589-96. , Formato Vancouver: Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012 Aug 23;120(8):1589-96.

Place Hold on Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients

By Ayala Díaz, Rosa María | García-Sesma Pérez-Fuentes, Álvaro | Jiménez Romero, Carlos | Martínez López, Joaquín | Moreno González, Enrique. BMC Gastroenterology, 2012 . 12:114. , Formato Vancouver: Ayala R, Grande S, Bustelos R, Ribera C, García-Sesma A, Jimenez C, et al. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. BMC Gastroenterol. 2012;12:114.

Place Hold on Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients

Response to imatinib mesylate in patients with hypereosinophilic syndrome.

By Martínez López, Joaquín. International Journal of Hematology, 2012 . 96(3):320-6. , Formato Vancouver: Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, et al. Response to imatinib mesylate in patients with hypereosinophilic syndrome. Int J Hematol. 2012 Sep;96(3):320-6.

Place Hold on Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

By Ayala Díaz, Rosa María | Canal López, Alicia | Castro Quismondo, Nerea | Grande García, Carlos | Martínez López, Joaquín | Rueda Fernández, Daniel. British Journal of Haematology, 2012 . 158(4):555-8. , Formato Vancouver: Martínez-López J, Castro N, Rueda D, Canal A, Grande C, Ayala R. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. Br J Haematol. 2012 Aug;158(4):555-8.

Place Hold on Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia

By Martínez López, Joaquín. Annals of Hematology, 2012 . 91(1):1-7. , Formato Vancouver: Fuster O, Barragán E, Bolufer P, Such E, Valencia A, Ibáñez M, et al. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. Ann Hematol. 2012;91(1):1-7.

Place Hold on Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín. Blood, 2012 . 120(13):2581-8. , Formato Vancouver: Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, López de la Guía A, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012 Sep 27;120(13):2581-8.

Place Hold on Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.